+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Research Report on China's Nicorandil Market, 2022-2031

  • PDF Icon

    Report

  • 50 Pages
  • July 2022
  • Region: China
  • China Research & Intelligence
  • ID: 5639686
In China, the crude incidence rate of hypertension among residents over the age of 18 is close to 30%, and the most common hazard of hypertension is coronary heart disease. By the end of 2021, it is estimated that the number of patients with coronary heart disease in China exceeded 11 million, and that number keeps rising due to environmental pollution and poor lifestyle habits.

Clinically, WHO classifies coronary heart disease into five types: asymptomatic myocardial ischemia (occult coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic heart disease), and sudden death.

Angina is a clinical syndrome caused by acute, temporary ischemia and hypoxia of the myocardium due to insufficient blood supply to the coronary arteries. Population-based studies show that the incidence of angina increases with age, with the prevalence increasing from 5%-7% in women aged 45-64 years to 10%-12% in women aged 65-84 years, and from 4%-7% in men aged 45-64 years to 12%-14% in men aged 65-84 years.

The rising number of patients with coronary heart disease in China has contributed to the growth of the related drug market.

Nicorandil is an anti-anginal drug that both relieves angina symptoms and improves the prognosis of coronary artery disease, with both nitrate-like effects and ATP-sensitive potassium channel-opening effects. It can both dilate large coronary arteries and diastole coronary microcirculatory resistance vessels, increasing coronary blood flow and myocardial oxygen supply while decreasing myocardial oxygen consumption, which effectively relieve angina pectoris. Several global medication guidelines have made high-level recommendations for Nicorandil.

Nicorandil was developed by Chugai with SIGMART as its trade name. Nicorandil tablets were launched in Japan in 1984 as an anti-anginal drug while the injection was put into clinical use for unstable angina in 1993 and acute heart failure in 2007. Nicorandil from Chugai entered the Chinese market in 2009, and generic drugs from local Chinese companies have been marketed since then. In 2017, Nicorandil became reimbursable under the Chinese medical insurance.

The analyst's survey data shows that from 2017 to 2021, the sales value of nicorandil in the Chinese market kept increasing year by year. Even in the face of COVID-19, the sales value still achieved growth in 2021, reaching CNY618 million (USD92.7 million), with a CAGR of 72.4% from 2017 to 2021. The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.

The analyst says that from 2022 to 2031, the number of patients with coronary heart disease and angina will continue to rise in China, and the demand for nicorandil in the Chinese market will keep growing.

Topics Covered:

  • The Impact of COVID-19 on China’s Nicorandil Market
  • Development Environment of Nicorandil in China
  • Sales Volume and value of Nicorandil in China
  • Sales Volume and Value of Nicorandil in China by Region
  • Major Nicorandil Manufacturers in China and Their Market Share
  • Sales Price of Nicorandil in China
  • Prospects of China’s Nicorandil Market, 2022-2031
Frequently Asked Questions about the Chinese Nicorandil Market

What is the estimated value of the Chinese Nicorandil Market?

The Chinese Nicorandil Market was estimated to be valued at CNY 803 Million in 2022.

What is the growth rate of the Chinese Nicorandil Market?

The growth rate of the Chinese Nicorandil Market is 15.0%, with an estimated value of CNY 2827 Million by 2031.

What is the forecasted size of the Chinese Nicorandil Market?

The Chinese Nicorandil Market is estimated to be worth CNY 2827 Million by 2031.

Who are the key companies in the Chinese Nicorandil Market?

Key companies in the Chinese Nicorandil Market include Beijing Sihuan Kebao Pharmaceutical Co., Ltd. (RuiKeXi®), Chugai Pharmaceutical Co., Ltd. (SIGMART®), Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin®) and Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang®).

Table of Contents

1 Relevant Concepts of Nicorandil
1.1 Indications of Nicorandil
1.2 Development of China’s Nicorandil Market
1.3 Governmental Approval of Nicorandil in China
1.4 The Impact of COVID-19 on China’s Nicorandil Market
2 Sales of Nicorandil in China, 2017-2021
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Nicorandil in China by Dosage Form, 2017-2021
2.3.1 Injection
2.3.2 Tablets
3 Analysis of Major Nicorandil Manufacturers in China, 2017-2021
3.1 Analysis of Market Share
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 Beijing Sihuan Kebao Pharmaceutical Co., Ltd.
3.2.1 Company Profile
3.2.2 Sales of Nicorandil in China
3.3 Chugai Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 Sales of Nicorandil in China
3.4 Xi'an Hanfeng Pharmaceutical Co., Ltd.
3.4.1 Company Profile
3.4.2 Sales of Nicorandil in China
3.5 Henan Topfond Pharmaceutical Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Nicorandil in China
3.6 Shanxi Xin Yu Pharmaceutical Co., Ltd.
3.6.1 Company Profile
3.6.2 Sales of Nicorandil in China
4 Sales Price of Nicorandil of Different Companies in China, 2021-2022
4.1 Beijing Sihuan Kebao Pharmaceutical Co., Ltd. (RuiKeXi®)
4.2 Chugai Pharmaceutical Co., Ltd. (SIGMART®)
4.3 Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin®)
4.4 Henan Topfond Pharmaceutical Co., Ltd. (TianFang®)
4.5 Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang®)
5 Prospects of China’s Nicorandil Market, 2022-2031
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information of Nicorandil in China
Chart Sales Value and Volume of Nicorandil in China, 2017-2021
Chart Sales Value of Nicorandil Injection in China, 2017-2021
Chart Sales Value of Nicorandil Tablets in China, 2017-2021
Chart Sales Value of Nicorandil Injection in China by Region, 2017-2021
Chart Sales Value of Nicorandil Tablets in China by Region, 2017-2021
Chart Sales Volume of Nicorandil Injection in China, 2017-2021
Chart Sales Volume of Nicorandil Tablets in China, 2017-2021
Chart Market Share of Nicorandil Injection Manufacturers in China by Sales Value, 2017-2021
Chart Market Share of Nicorandil Tablets Manufacturers in China by Sales Value, 2017-2021
Chart Sales Value and Volume of Nicorandil (of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.) in China, 2017-2021
Chart Sales Value and Volume of Nicorandil (of Chugai Pharmaceutical Co., Ltd.) in China, 2017-2021
Chart Sales Value and Volume of Nicorandil (of Shanxi Xin Yu Pharmaceutical Co., Ltd.) in China, 2017-2021
Chart Sales Value and Volume of Nicorandil (of Xi'an Hanfeng Pharmaceutical Co., Ltd.) in China, 2017-2021
Chart Sales Value and Volume of Nicorandil (of Henan Topfond Pharmaceutical Co., Ltd.) in China, 2017-2021
Chart Sales Price of Nicorandil (of Shanxi Xin Yu Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
Chart Sales Price of Nicorandil (of Chugai Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
Chart Sales Price of Nicorandil (of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
Chart Forecast on Sales Value of Nicorandil in China, 2022-2031
Chart Forecast on Sales Volume of Nicorandil in China, 2022-2031

Companies Mentioned

  • Beijing Sihuan Kebao Pharmaceutical Co., Ltd. (RuiKeXi®)
  • Chugai Pharmaceutical Co., Ltd. (SIGMART®)
  • Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin®)
  • Henan Topfond Pharmaceutical Co., Ltd. (TianFang®)
  • Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang®)

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...